Jiang Xinxin Medtec Co (SZSE:300453) ROCE % : 19.33% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Jiang Xinxin Medtec Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiang Xinxin Medtec Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 19.33%.

Jiang Xinxin Medtec Co ROCE % Historical Data

The historical data trend for Jiang Xinxin Medtec Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiang Xinxin Medtec Co ROCE % Chart

Jiang Xinxin Medtec Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

12.11

19.06

20.67

20.01

18.89

Jiang Xinxin Medtec Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															19.08	23.18	17.69	17.47	19.33

Jiang Xinxin Medtec Co ROCE % Calculation

Jiang Xinxin Medtec Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	257.29	/	( ( (1787.058 - 528.994)	+	(2030.808 - 564.953) )	/ 2 )
	=	257.29	/	( (1258.064	+	1465.855)	/ 2 )
	=	257.29	/	1361.9595
	=	18.89 %

Jiang Xinxin Medtec Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	304.376	/	( ( (2040.476 - 488.721)	+	(2158.083 - 560.385) )	/ 2 )
	=	304.376	/	( ( 1551.755	+	1597.698 )	/ 2 )
	=	304.376	/	1574.7265
	=	19.33 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Jiang Xinxin Medtec Co (SZSE:300453) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jiang Xinxin Medtec Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jiang Xinxin Medtec Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiang Xinxin Medtec Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jiang Xi Sanxin Medtec Co Ltd (SZSE:300453) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Fushan Avenue, Xiaolan Economic Development Zone, Nanchang County, Jiangxi Province, Nanchang, CHN, 330200

Website

http://www.sanxin-med.com

Jiang Xi Sanxin Medtec Co Ltd is engaged in researching and developing, manufacturing and marketing of medical devices. Its products include four series: blood purification, indwelling catheters, injections, infusion and blood transfusion. Blood purification products are used in clinical dialysis treatment for uremic patients. Indwelling catheter products represented by venous indwelling needles, positive pressure indwelling needles, central venous catheters. Injectable products mainly include self-destructing syringes, retracting self-destructing syringes, conjoined syringes.

Executives

Zhang Lin	Supervisors
Le Zhen Rong	Executives
Mao Zhi Ping	Directors, executives
Yu Zhen Zhu	Supervisors
Peng Yi Xing	Director
Liu Ming	Securities Affairs Representative
Wan Xiao Ping	Director
Wang Qin Hua	Supervisors
Xiong Yan	Supervisors

Jiang Xinxin Medtec Co Headlines

No Headlines